Wedbush Analysts Reduce Earnings Estimates for Impel NeuroPharma, Inc. (NASDAQ:IMPL)

Impel NeuroPharma, Inc. (NASDAQ:IMPLGet Rating) – Wedbush cut their Q1 2022 earnings estimates for Impel NeuroPharma in a research report issued on Thursday, April 28th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($1.08) per share for the quarter, down from their previous forecast of ($1.07). Wedbush also issued estimates for Impel NeuroPharma’s Q2 2022 earnings at ($1.13) EPS, Q3 2022 earnings at ($0.99) EPS and FY2022 earnings at ($4.11) EPS.

Separately, Zacks Investment Research upgraded Impel NeuroPharma from a “sell” rating to a “hold” rating in a report on Friday, March 25th.

Shares of IMPL stock opened at $6.34 on Monday. The company has a fifty day moving average price of $6.77. The company has a quick ratio of 5.75, a current ratio of 5.93 and a debt-to-equity ratio of 0.56. The stock has a market cap of $146.92 million and a price-to-earnings ratio of -0.34. Impel NeuroPharma has a fifty-two week low of $5.72 and a fifty-two week high of $34.75.

Impel NeuroPharma (NASDAQ:IMPLGet Rating) last announced its quarterly earnings data on Thursday, March 24th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.21). The business had revenue of $0.58 million during the quarter, compared to the consensus estimate of $1.89 million.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Impel NeuroPharma by 32.1% during the 4th quarter. BlackRock Inc. now owns 355,077 shares of the company’s stock worth $3,064,000 after purchasing an additional 86,347 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in Impel NeuroPharma during the 4th quarter valued at about $92,000. Millennium Management LLC boosted its holdings in Impel NeuroPharma by 43.8% during the 4th quarter. Millennium Management LLC now owns 14,827 shares of the company’s stock valued at $128,000 after acquiring an additional 4,513 shares during the period. Point72 Hong Kong Ltd purchased a new position in Impel NeuroPharma during the 4th quarter valued at about $51,000. Finally, Point72 Asset Management L.P. purchased a new position in Impel NeuroPharma during the 4th quarter valued at about $1,802,000. 78.47% of the stock is owned by hedge funds and other institutional investors.

Impel NeuroPharma Company Profile (Get Rating)

Impel NeuroPharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.

Featured Stories

Earnings History and Estimates for Impel NeuroPharma (NASDAQ:IMPL)

Receive News & Ratings for Impel NeuroPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel NeuroPharma and related companies with's FREE daily email newsletter.